ITM Isotope Technologies Munich SE has appointed Andrew Cavey, MD, as its CEO.
Andrew Cavey, MD. Image courtesy of ITM Isotope Technologies Munich SE.
The appointment is effective September 1. He replaces Steffen Schuster, who will step up to the company’s supervisory board. Cavey will lead the company's next stages of growth as it broadens and advances its targeted radiopharmaceutical pipeline and expands its medical radioisotope manufacturing capabilities.
Cavey previously worked at Bristol Myers Squibb as senior vice president, head of global program leaders, hematology, oncology, cell therapy. Prior to that, he held several leadership positions at Novartis over the course of 11 years, culminating in his role as global program head, prostate cancer.
Cavey holds physiological sciences and medical degrees from Oxford University in England and a Master’s in Public Health from Harvard University in Massachusetts. He is a member of the U.K.'s Royal College of Physicians and currently serves as a board trustee for Parkinson’s U.K.
